Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.

Molecular medicine reports - 1 Jan 2023

Hu Xianhua, Zhang Rendan, Yao Jiaxin, Mu Bo, Zhao Chunyan

Abstract excerpt

Kirsten rat sarcoma virus (KRAS) mutation is considered to be the event that leads to the initiation of pancreatic ductal adenocarcinoma (PDAC), the mutation frequency of the KRAS gene in PDAC is 90‑95%. Studies have shown that wild‑type KRAS (KRASWT) has a survival advantage in PDAC and can antagonize the effect of mutated KRAS G12D (KRASG12D), leading to a low cell transformation efficiency. The present study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Wnt Signaling Pathway

Source

Open in PubMed Open full text

Identifiers

PMID: 36367161
DOI: 10.3892/mmr.2022.12891
PMCID: PMC9673065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.PMID 36367161Read ↗

Critical role of KRAS mutation in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read ↗

Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review).Semantic proximity Read ↗

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read ↗

Critical role of oncogenic KRAS in pancreatic cancer (Review).Semantic proximity Read ↗

The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.Semantic proximity Read ↗

KRAS-dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS InhibitorsSemantic proximity Read ↗

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progressionSemantic proximity Read ↗

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of TherapySemantic proximity Read ↗

Kras as a key oncogene and therapeutic target in pancreatic cancerSemantic proximity Read ↗

KRAS in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.